Interleukin-1&bgr; Is Crucial for the Induction of Coronary Artery Inflammation in a Mouse Model of Kawasaki Disease

No abstract is available for this paper.

• Publication year

  2012

• Venue

  Circulation

• Publication date

  2012-02-23

• Fields of study

  Medicine

• Identifiers
  DOI 10.1161/CIRCULATIONAHA.111.072769PMID 22361326PMCID PMC3337219
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Infliximab for intravenous immunoglobulin resistance in Kawasaki disease: a retrospective study.

  2011cited by this paper
• Role of IL-1 Beta in the Development of Human TH17 Cells: Lesson from NLPR3 Mutated Patients

  2011cited by this paper
• Transcript abundance patterns in Kawasaki disease patients with intravenous immunoglobulin resistance.

  2010cited by this paper
• Long-term prognosis of Kawasaki disease: increased cardiovascular risk?

  2010cited by this paper
• Targeting IL-1beta in disease; the expanding role of NLRP3 inflammasome.

  2010cited by this paper
• IL-1B polymorphism in association with initial intravenous immunoglobulin treatment failure in Taiwanese children with Kawasaki disease.

  2010cited by this paper
• The long pentraxin PTX3: a modulator of the immunoinflammatory response in atherosclerosis and cardiovascular diseases.

  2010cited by this paper
• Pentraxins in innate immunity: lessons from PTX3

  2010cited by this paper
• Involvement of Innate and Adaptive Immunity in a Murine Model of Coronary Arteritis Mimicking Kawasaki Disease1

  2009cited by this paper
• The role of IL-1 in the pathogenesis of heart disease

  2009cited by this paper
• Kawasaki Disease update

  2009cited by this paper
• When children with Kawasaki disease grow up: Myocardial and vascular complications in adulthood.

  2009cited by this paper
• Critical regulation of early Th17 cell differentiation by interleukin-1 signaling.

  2009cited by this paper
• Treatment of Kawasaki Disease: Analysis of 27 US Pediatric Hospitals From 2001 to 2006

  2009cited by this paper
• Anakinra for Rheumatoid Arthritis: A Systematic Review

  2009cited by this paper
• Searching for the cause of Kawasaki disease — cytoplasmic inclusion bodies provide new insight

  2008cited by this paper
• RNA-Containing Cytoplasmic Inclusion Bodies in Ciliated Bronchial Epithelium Months to Years after Acute Kawasaki Disease

  2008cited by this paper
• Long-term outcome of Kawasaki disease.

  2008cited by this paper
• Infliximab treatment for refractory Kawasaki disease with coronary artery aneurysm.

  2008cited by this paper
• Resistance to intravenous immunoglobulin in children with Kawasaki disease.

  2008cited by this paper
• Activated myeloid dendritic cells accumulate and co-localize with CD3+ T cells in coronary artery lesions in patients with Kawasaki disease.

  2007cited by this paper
• Gene-expression patterns reveal underlying biological processes in Kawasaki disease

  2007cited by this paper
• TNF-α Is Necessary for Induction of Coronary Artery Inflammation and Aneurysm Formation in an Animal Model of Kawasaki Disease1

  2006cited by this paper
• TLR2 and MyD88 Contribute to Lactobacillus casei Extract–Induced Focal Coronary Arteritis in a Mouse Model of Kawasaki Disease

  2005cited by this paper
• Cloning the Arterial IgA Antibody Response during Acute Kawasaki Disease1

  2005cited by this paper
• Presence of IFN-γ Does Not Indicate Its Necessity for Induction of Coronary Arteritis in an Animal Model of Kawasaki Disease1

  2004cited by this paper
• Kawasaki syndrome.

  2004cited by this paper
• Is there a role for corticosteroids in Kawasaki disease?

  2003cited by this paper
• Initial intravenous gammaglobulin treatment failure in Kawasaki disease.

  2000cited by this paper
• Intravenous gamma-globulin treatment and retreatment in Kawasaki disease. US/Canadian Kawasaki Syndrome Study Group.

  1998cited by this paper
• Sequelae of Kawasaki disease in adolescents and young adults.

  1996cited by this paper
• Effects of immunoglobulin and gamma-interferon on the production of tumour necrosis factor-α and interleukin-1β by peripheral blood monocytes in the acute phase of Kawasaki disease

  1996cited by this paper
• Long-term consequences of Kawasaki disease. A 10- to 21-year follow-up study of 594 patients.

  1996cited by this paper
• IgG Induction of IL‐1 Receptor Antagonist Production by Human Monocytes

  1994cited by this paper
• Suppressive effect of intravenous immunoglobulins on the activity of interleukin-1

  1994cited by this paper
• The Clinical Perspective

  1994cited by this paper
• Gamma globulin re-treatment in Kawasaki disease.

  1993cited by this paper
• Can we prevent long term cardiac damage in Kawasaki disease? Lessons from Lactobacillus casei cell wall-induced arteritis in mice.

  1993cited by this paper
• A novel heterodimeric cysteine protease is required for interleukin-1βprocessing in monocytes

  1992cited by this paper
• A single intravenous infusion of gamma globulin as compared with four infusions in the treatment of acute Kawasaki syndrome.

  1991cited by this paper
• Kawasaki syndrome.

  1990cited by this paper
• Endothelial cell activation and high interleukin-1 secretion in the pathogenesis of acute Kawasaki disease.

  1989cited by this paper
• Animal models of vasculitis. Lessons we can learn to improve our understanding of Kawasaki disease.

  1988cited by this paper
• Circulating interleukin-1 beta in patients with Kawasaki disease.

  1988cited by this paper
• Plasma prostaglandin E2 level in Kawasaki disease.

  1988cited by this paper
• The treatment of Kawasaki syndrome with intravenous gamma globulin.

  1986cited by this paper
• The treatment of Kawasaki syndrome with intravenous gamma globulin.

  1986cited by this paper
• Coronary arteritis in mice following the systemic injection of group B Lactobacillus casei cell walls in aqueous suspension.

  1985cited by this paper
• AN ANIMAL MODEL OF KAWASAKI DISEASE

  1984cited by this paper
• A new infantile acute febrile mucocutaneous lymph node syndrome (MLNS) prevailing in Japan.

  1974cited by this paper

• IL-33 blockade attenuates vascular inflammation in a mouse model of Kawasaki disease vasculitis.

  2026cites this paper
• Dynamic assessment of myocardial contractile dysfunction and its recovery after IVIG treatment in a murine model of Kawasaki disease using high-resolution speckle-tracking echocardiography

  2026cites this paper
• Protective Effects of Jiawei Baihu Tang in Kawasaki Disease: Omics Analysis and Mechanistic Exploration.

  2026cites this paper
• Sirtuin 1 Activation Mitigates Murine Vasculitis Severity by Promoting Autophagy and Mitophagy

  2025cites this paper
• Fenofibrate mitigates the dysfunction of high glucose-driven human retinal microvascular endothelial cells by suppressing NLRP3 inflammasome.

  2025cites this paper
• Anakinra for infants under six months with Kawasaki disease and coronary artery lesions: a multicenter case series and literature review

  2025cites this paper
• AIM2 Targeting of Nuclear DNA Leakage in Dendritic Cells Exacerbates Vasculitis in a Murine Model of Kawasaki Disease.

  2025cites this paper
• Pathology of the Coronary Arteries and Myocardium in Kawasaki Disease.

  2025cites this paper
• Chrysin improves endothelial inflammation via the NFAT pathway in Kawasaki disease

  2025cites this paper
• Intestinal Microbiota Contributes to the Development of Cardiovascular Inflammation and Vasculitis in Mice

  2025cites this paper
• Gut Microbiota Alterations in Patients With Kawasaki Disease

  2025cites this paper
• Identification of m6A-related biomarkers in Kawasaki disease.

  2025cites this paper
• OGG1-driven pathogenesis in Kawasaki Disease: Identification and pharmacological regulation of a molecular marker validated in transgenic mice and clinical models.

  2025cites this paper
• Kawasaki Disease Vasculitis: From Diagnosis to New Concepts in Pathophysiology and Therapeutic Approaches.

  2025cites this paper
• The Caveolin-1/NF-κB signalling pathway is involved in Kawasaki disease vasculitis induced by Lactobacillus casei cell wall extract.

  2025cites this paper
• Mechanistic role of pyroptosis in Kawasaki disease: An integrative bioinformatics analysis of immune dysregulation, machine learning-based biomarker discovery, WGCNA, and drug repurposing insights

  2025cites this paper
• Variant rs13045 reduces EIF2AK3 expression and inhibits pro-inflammatory cytokine secretion via the MAPK-ERK1/2 pathway in Kawasaki disease.

  2025cites this paper
• Dimethyl itaconate attenuates IL-1-induced IVIG-resistant inflammation in a coronary artery cell model of Kawasaki disease.

  2025cites this paper
• Regulation of pyroptosis by natural products in atherosclerosis: mechanisms and therapeutic potential

  2025cites this paper
• NOD1 deficiency promotes inflammation via autophagic degradation of ASK1

  2025cites this paper
• The protective role of steroids on coronary arteries in the acute phase of Kawasaki disease for high risk patients: a retrospective study

  2025cites this paper
• Small kid, giant aneurysms: anakinra treatment in IVIG-resistant Kawasaki disease

  2025cites this paper
• Pyroptosis in Kawasaki disease: from mechanisms to targeted interventions

  2025cites this paper
• Associations of Gla-rich protein and interleukin-1β with coronary artery calcification risk in patients with suspected coronary artery disease

  2025cites this paper
• Innate and adaptive immunity in acute myocarditis.

  2024cites this paper
• Single-Cell Transcriptome Reveals Potential Mechanisms for Coronary Artery Lesions in Kawasaki Disease

  2024cites this paper
• Activation of HIF2 leads to vascular remodeling and inflammation, coronary thrombosis and arterial dilation, recapitulating cardiac involvement of Kawasaki disease

  2024cites this paper
• Cutaneous signs of selected cardiovascular disorders: A narrative review

  2024cites this paper
• Platelets in Kawasaki disease: mediators of vascular inflammation

  2024influential citation
• Platelet–Monocyte Aggregate Instigates Inflammation and Vasculopathy in Kawasaki Disease

  2024cites this paper
• Long-term cardiovascular inflammation and fibrosis in a murine model of vasculitis induced by Lactobacillus casei cell wall extract

  2024cites this paper
• The central role of Interleukin-1 signaling in the pathogenesis of Kawasaki disease vasculitis: Path to Translation.

  2024cites this paper
• Role of inflammasomes in endothelial dysfunction

  2024cites this paper
• Redundant role of PAD2 and PAD4 in the development of cardiovascular lesions in a mouse model of Kawasaki Disease vasculitis.

  2024cites this paper
• The role of the ER stress sensor IRE1 in cardiovascular diseases

  2024cites this paper
• Enhanced CD95 and interleukin 18 signalling accompany T cell receptor Vβ21.3+ activation in multi-inflammatory syndrome in children

  2024cites this paper
• Role of Pyroptosis in IVIG-Resistant Kawasaki Disease and the Establishment of a New Predictive Model

  2024cites this paper
• Research perspective in the clinical management of Kawasaki disease

  2024cites this paper
• A novel format of TNF-α binding affibody molecule ameliorate coronary artery endothelial injury in a mouse model of Kawasaki disease.

  2024cites this paper
• Long COVID Definition, Symptoms, Risk Factors, Epidemiology and Autoimmunity: A Narrative Review

  2024cites this paper
• Kawasaki Disease-Associated Cytokine Storm Syndrome.

  2024cites this paper
• Macrophage Activation Syndrome in the Setting of Rheumatic Diseases.

  2024cites this paper
• Emerging evidence of microbial infection in causing systematic immune vasculitis in Kawasaki disease

  2023cites this paper
• Mitochondrial quality control in health and cardiovascular diseases

  2023cites this paper
• Potential roles of NLRP3 inflammasome in the pathogenesis of Kawasaki disease

  2023cites this paper
• Roles of pyroptosis in atherosclerosis pathogenesis.

  2023cites this paper
• The activation of CaN/NFAT signaling pathway in macrophages aggravated Lactobacillus casei cell wall extract-induced Kawasaki disease vasculitis.

  2023cites this paper
• Kawasaki Disease and Innate Immunity

  2023cites this paper
• Mercury increases IL-1β and IL-18 secretion and intensifies coronary arteritis in an animal model of Kawasaki disease

  2023cites this paper
• Identification and validation of autophagy-related genes in Kawasaki disease

  2023cites this paper
• CircRNA7632 down-regulation alleviates endothelial cell dysfunction in Kawasaki disease via regulating IL-33 expression

  2023cites this paper
• Multisystem Inflammatory Syndrome therapies in children (MISTIC): A randomized trial

  2023cites this paper
• Platelets exacerbate cardiovascular inflammation in a murine model of Kawasaki disease vasculitis

  2023cites this paper
• The role of FOXO4/NFAT2 signaling pathway in dysfunction of human coronary endothelial cells and inflammatory infiltration of vasculitis in Kawasaki disease

  2023cites this paper
• Increased Myosin light chain 9 expression during Kawasaki disease vasculitis

  2023cites this paper
• Escin ameliorates inflammation via inhibiting mechanical stretch and chemically induced Piezo1 activation in vascular endothelial cells.

  2023cites this paper
• The neutrophil: A key resourceful agent in immune‐mediated vasculitis

  2022cites this paper
• Pathogenic and therapeutic roles of cytokines in Kawasaki diseases.

  2022cites this paper
• Efficacy of Anakinra on Multiple Coronary Arteries Aneurysms in an Infant with Recurrent Kawasaki Disease, Complicated by Macrophage Activation Syndrome

  2022cites this paper
• Exploration of Potential Biomarker Genes and Pathways in Kawasaki Disease: An Integrated in-Silico Approach

  2022cites this paper
• The role of mitochondria in the pathogenesis of Kawasaki disease

  2022cites this paper
• Impact of Kawasaki disease on juvenile idiopathic arthritis in real-world patients: A population-based cohort study

  2022cites this paper
• Predictive Role of IL-2R and IL-10 in the Anti-inflammatory Response and Antiplatelet Therapy of Kawasaki Disease: A Retrospective Study

  2022cites this paper
• Targeting IRE1 endoribonuclease activity alleviates cardiovascular lesions in a murine model of Kawasaki disease vasculitis

  2022cites this paper
• Sustained release of Lactobacillus casei cell wall extract can induce a continuous and stable IgA deposition model

  2022cites this paper
• Partnerships in the Comprehensive Management of Multisystem Inflammatory Syndrome in Neonates (MIS-N): Translating 2 Years of Pediatric Practice to the Neonatal Wards

  2022cites this paper
• Double Coronary Aneurisms in Kawasaki Disease Successfully Treated with Anakinra: A Case Report

  2022cites this paper
• Non‐coding RNAs in Kawasaki disease: Molecular mechanisms and clinical implications

  2022cites this paper
• Kawasaki Disease

  2021cites this paper
• Pyroptosis: A New Regulating Mechanism in Cardiovascular Disease

  2021cites this paper
• Epigenetics in Kawasaki Disease

  2021cites this paper
• CDCP1 on Dendritic Cells Contributes to the Development of a Model of Kawasaki Disease

  2021cites this paper
• Particularités cutanées des maladies de système de l’enfant

  2021cites this paper
• NLRP3 inflammasome as a key driver of vascular disease.

  2021cites this paper
• The everchanging framework of autoinflammation

  2021cites this paper
• Red Blood Cell Distribution Width as a Predictive Marker for Coronary Artery Lesions in Patients with Kawasaki Disease

  2021cites this paper
• Characterization of the T Cell Response to Lactobacillus casei Cell Wall Extract in Children With Kawasaki Disease and Its Potential Role in Vascular Inflammation

  2021cites this paper
• Autophagy-mitophagy induction attenuates cardiovascular inflammation in a murine model of Kawasaki disease vasculitis

  2021influential citation
• Neutropenia Is Not Associated With the Outcomes in Patients With Kawasaki Disease

  2021cites this paper
• Putative regulatory functions of SNPs associated with bronchial asthma, arterial hypertension and their comorbid phenotype

  2021cites this paper
• New Advances and Ongoing Challenges in the Use of Biologic Agents in Cardiac Sarcoidosis and Other Inflammatory Cardiomyopathies

  2021cites this paper
• Mitochondrial quality surveillance: mitophagy in cardiovascular health and disease

  2021cites this paper
• Recombinant Human Soluble Thrombomodulin Suppresses Arteritis in a Mouse Model of Kawasaki Disease

  2021cites this paper
• NLRP3 Inflammasome Mediates Immune-Stromal Interactions in Vasculitis

  2021cites this paper
• Association between serum miR-221-3p and intravenous immunoglobulin resistance in children with Kawasaki disease

  2021cites this paper
• Early anti IL-1 treatment replaces steroids in refractory Kawasaki disease: clinical experience from two case reports

  2021cites this paper
• Inhibition of IL-6 in the LCWE Mouse Model of Kawasaki Disease Inhibits Acute Phase Reactant Serum Amyloid A but Fails to Attenuate Vasculitis

  2021influential citation
• MicroRNA-223 Regulates the Development of Cardiovascular Lesions in LCWE-Induced Murine Kawasaki Disease Vasculitis by Repressing the NLRP3 Inflammasome

  2021cites this paper
• KCa3.1 Inhibition of Macrophages Suppresses Inflammatory Response Leading to Endothelial Damage in a Cell Model of Kawasaki Disease

  2021cites this paper
• Anakinra treatment in patients with acute Kawasaki disease with coronary artery aneurysms: A Phase I/IIa trial.

  2021cites this paper
• Platelets Fuel the Inflammasome Activation of Innate Immune Cells

  2020cites this paper
• Antibodies and Immunity During Kawasaki Disease

  2020cites this paper
• Inflammasomes and Pyroptosis as Therapeutic Targets for COVID-19

  2020cites this paper
• Novel Pharmacotherapies for Recurrent Pericarditis: Current Options in 2020

  2020cites this paper
• Kawasaki disease: pathophysiology and insights from mouse models

  2020cites this paper
• Neutrophil-Derived Semaphorin 4D Induces Inflammatory Cytokine Production of Endothelial Cells via Different Plexin Receptors in Kawasaki Disease

  2020cites this paper
• A comparative clinical trial to assess a standardized escalation dose strategy of interleukin-1 blockade in Kawasaki disease: The ANACOMP trial

  2020cites this paper
• Lipocalin-2-induced proliferative endoplasmic reticulum stress participates in Kawasaki disease-related pulmonary arterial abnormalities

  2020cites this paper
• The diagnostic role of AIM2 in Kawasaki disease

  2020cites this paper
• Efficacy of infliximab in the treatment of Kawasaki disease: A systematic review and meta-analysis

  2020influential citation